MOUNT OLIVE, N.J., July 17, 2013 /PRNewswire via COMTEX/ -- Flowonix Medical, Inc., announced today that initial patients implanted during the clinical study with the Prometra implantable intrathecal ...

Study design: Retrospective single centre study. Objectives: To evaluate a low-dose radioisotope imaging procedure for assessment of implanted intrathecal drug delivery and to compare the radiation ...

Credit: Getty Images. Researchers conducted a retrospective cohort study to assess the impact of an implantable pump on opioid consumption in patients with chronic noncancer pain. Use of an ...

DUBLIN, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced the launch of Efficio™, a cloud-based data management software for use with the SynchroMed™ II intrathecal drug ...

March 25, 2008 — A class 1 recall has been announced for Medtronic Neuromodulation's implantable infusion pumps, the US Food and Drug Administration (FDA) announced on March 21. The action was based ...

high-frequency spinal cord stimulation controller Intrathecal drug delivery systems and spinal cord stimulation have shown promise for the treatment of cancer pain in initial studies. Cancer-related ...

A study presented at the American Academy of Pain Medicine’s 26th annual meeting investigated methods for reducing the estimated $1 billion spent annually on pain care treatment in the United States ...

Eli Lilly is plowing a further $50 million into its research collaboration with Purdue University, signing up to work with its partner for another five years on challenges including intrathecal and ...

Intrathecal drug administration via lumbar puncture and a spinal access port device led to serious complications in a patient receiving experimental therapy for Niemann-Pick type C. In a case report ...

ST. PAUL, Minn.--(BUSINESS WIRE)-- Today, CNS Therapeutics announced the FDA approval of Gablofen® (baclofen injection) for use in the management of severe spasticity, giving healthcare providers a ...

On the heels of FDA approval of its new anti-spasticity drug Gablofen, CNS Therapeutics has raised $3 million in equity, according to documents filed with the Securities and Exchange Commission.